Precigen, Inc.
Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company developing and commercializing precision medicines for immuno-oncology, autoimmune disorders and infectious diseases. Its first commercial product, Papzimeos, is an adenoviral-vector immunotherapy approved in the United States for adults with… From the company’s description.
Over the twelve months to Sep 30, 2026, Precigen, Inc. reported revenue of $156.94M, up 2387.6% from a year earlier, and net income of $24.41M. Its operating margin was 21.4%, and operations used $73.21M in cash. In fiscal 2025, it reported revenue of $9.68M, up 146.7% from fiscal 2024, and a net loss of $250.64M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Precigen, Inc. does
In the company’s own words
Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company developing and commercializing precision medicines for immuno-oncology, autoimmune disorders and infectious diseases. Its first commercial product, Papzimeos, is an adenoviral-vector immunotherapy approved in the United States for adults with recurrent respiratory papillomatosis, a disease caused by HPV 6 or HPV 11 infection. Precigen markets Papzimeos to healthcare providers and supports patients with services including insurance navigation and financial assistance. Its clinical pipeline includes PRGN-2009, an investigational immunotherapy for HPV-associated cancers, and PRGN-3006, an investigational CAR-T therapy for blood cancers. The company’s AdenoVerse platform delivers therapeutic genes using engineered adenovectors, while UltraCAR-T is a non-viral cell therapy platform designed for rapid, decentralized manufacturing. Supporting technologies include UltraVector for genetic program design, UltraPorator for cell processing, and RheoSwitch for regulating gene expression. Precigen also operates internal manufacturing capabilities for AdenoVerse-based therapies. Its brands and technology platforms include Papzimeos, AdenoVerse, UltraCAR-T, UltraVector, UltraPorator and RheoSwitch.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- GERMANTOWN, MD
- Fiscal year end
- December
- CIK
- 1356090
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Precigen, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Precigen, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Precigen, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Precigen, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Precigen, Inc.'s last four quarterly filings that the numbers alone won't show?”